However, due to the early termination of the study, the primary aim was amended to explore whether proinsulin concentrations at 16–18 weeks would help identify or risk stratify high-risk pregnant women who go on to develop GDM according to NICE criteria. The gene discussed is INS; the disease is gestational diabetes.